Navigation Links
New Molecular Treatment Identified To Treat Blood Cell Cancers

According to the new study it was found that researchers at the UC Davis Cancer Center have identified a peptide (short sequence of amino acids // . The speciality of this discovery is that the peptide is found to have high affinity, stability and specificity towards leukemic and lymphoma cells. Hence researchers say that this discovery can be used to image tumors and deliver anti-cancer drugs.

The study results were published in the journal Nature Chemical Biology. ‘We believe that this peptide has great potential for becoming a new, effective imaging and therapeutic agent for patients with lymphoid cancers,’ said Kit Lam, professor and chief of hematology and oncology at UC Davis Cancer Center and senior author of the paper. The peptide – named LLP2A by Lam – binds to a receptor found on the surface of lymphocytes. In the Nature Chemical Biology paper, Lam reports that LLP2A is attracted specifically to malignant lymphocytes, not healthy ones. The next step will be to evaluate the binding of LLP2A in a larger number of human lymphoma biopsy samples. If those results are positive, Lam plans to test the peptide as a lymphoma imaging agent in patients.

Experiments are already under way at the UC Davis School of Veterinary Medicine to evaluate LLP2A in dogs with naturally occurring non-Hodgkin's lymphoma. In addition, Lam and his colleagues have begun testing the peptide as a drug-delivery vehicle for lymphoma tumors in mice. LLP2A is intended to work like a monoclonal antibody – but a peptide is much smaller than an antibody and has the potential to infiltrate cancer cells more successfully. Monoclonal antibodies, engineered to lock onto a specific target molecule, are used to carry radioactive isotopes or anti-cancer drugs directly to a tumor. Three monoclonal antibodies, rituximab (Rituxan), ibritumomab tiuxetan (Zevalin), and tositumomab (Bexxar), have already been approved by the Food and Drug Administration for the treatment of B-cell lymphom a.

These antibodies have drawbacks, however: They bind to healthy lymphocytes along with malignant ones; in addition, they do not bind to T cells and therefore can't be used to treat T-cell lymphoma. In contrast, LLP2A binds to both B-cell and T-cell lymphoid cancer lines, and has low affinity for normal T or B lymphocytes. It also has lower uptake in the liver and spleen than the monoclonal antibodies now on the market for lymphoma treatment. ‘We believe LLP2A may be an ideal vehicle for the delivery of radionuclides, cytotoxic agents, toxins, cytokines and nanoparticles to lymphoid cancers which include non-Hodgkin's lymphoma and acute lymphocytic leukemia,’ Lam said.

In their paper, Lam and his colleagues report that they have already used LLP2A to successfully image lymphoid tumors in living mice. The researchers coupled near-infrared fluorescent dyes to LLP2A peptides; when the dye-tagged peptides found and locked onto a tumor, the tumor became visible to a near-infrared scanner. LLP2A was identified using a combinatorial chemistry method Lam developed more than a decade ago. Known as the ‘one-bead-one-compound’ method, Lam's technique allows scientists to synthesize millions of novel compounds in less than a week and analyze them in a few days.

(Source: Eurealert)
'"/>




Related medicine news :

1. Molecular markers for early diagnosis of breast and ovarian cancer
2. Scientists Developed Map For Brain Molecular Communities
3. Molecular Mechanism Of HIV Infecting The Healthy Cells Discovered.
4. Molecular Flaw Detected in Aggressive Breast Cancers
5. Molecular Computer Developed To perform Calculations From Within Human Body
6. Molecular Imaging Of Cancer Now Possible, New Hybrid Virus Produced
7. Molecular Basis Of ALS Found
8. Researchers Find Molecular "Brake" to Cell Death
9. Solitons Could Power Molecular Electronics, Artificial Muscles
10. Discovery of Agile Molecular Motors Could Aid in Treating Motor Neuron Diseases
11. Joint Center for Molecular Modeling Instituted by Burnham Institute for Medical Research & UC San Diego
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/26/2017)... ... 26, 2017 , ... After raising nearly $30,000 on Kickstarter , about ... available at a discounted crowdfunding price on Indiegogo . , “Along with creating ... wanted to bring a fidget toy to the market that was made of superior ...
(Date:5/26/2017)... ... 2017 , ... Dr. Alex Rabinovich, a highly-skilled oral surgeon specializing in wisdom ... on insurance options. If a Bay Area patient has to search for a second ... Visiting an in-network provider for a second opinion can ensure a patient receives the ...
(Date:5/26/2017)... ... ... in the Garden of Eden”: retells the stories of three Bible figures in modern terms. ... Penelope Colt, mother, trader, horse farmer, artist and a former GM journeyman. Born in ... six, they moved to Dayton, Ohio, where Penny graduated high school. At sixteen, she ...
(Date:5/24/2017)... ... May 24, 2017 , ... In modern ... the most appropriate instruments for research and understanding the basic principles that were ... will focus on innovations in stereo microscopy for brightfield and fluorescence typically used ...
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... ... dental implants in Bayside, NY, who have now spent 10 years as clinical ... New York University (NYU) College of Dentistry. Through the program, private practitioners receive ...
Breaking Medicine News(10 mins):
(Date:5/24/2017)... 24, 2017  ivWatch LLC today announced the ... Board to enable seamless integration of ivWatch,s groundbreaking ... infusion pumps and other devices. By integrating ivWatch ... to help health care customers deliver a higher ... to IV therapy. "The ivWatch OEM ...
(Date:5/18/2017)... 2017  Bayer announced today that the latest research ... at the 53 rd Annual Meeting of the ... 2-6 in Chicago . ... colorectal, liver and thyroid cancers, as well as lymphomas, ... CHRONOS-1 trial of copanlisib in patients with relapsed or ...
(Date:5/10/2017)... MARLBOROUGH, Mass., May 10, 2017 Hologic, Inc. ... financial results for the fiscal second quarter ended April ... (EPS) of $1.84 increased 666.7% compared to the prior ... business resulted in a significant gain, while non-GAAP diluted ... increased 3.2%, or 3.8% in constant currency terms.  Excluding ...
Breaking Medicine Technology: